Article Text
PDF
Abstract
Introduction/Background Over the last three decades, peritoneal surface malignancy treatment has undergone considerable change. Presently, palliative measures dominate peritoneal carcinomatosis (PC) management. This involves two primary intraperitoneal chemotherapy approaches: cytoreductive surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), established as the gold standard in many PC cases, and Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC), holding promise for minimally invasive, secure drug delivery. Progress in these techniques stems from multicenter studies and clinical trials, offering valuable insights. Noteworthy strides in method development, particularly through nanomedicine and nanoparticles, highlight this study’s emphasis on refining PC treatment strategies. Nano Aerosol Chemotherapy (NAC) exhibits distinctive features, including patented technology, precise nanometer particle size uniformity, gravity-based drug delivery, cost-effectiveness, and enhanced drug reach via the Nanowand’s maneuverability, showcasing its potential in advancing PC treatment.
Methodology From July 2022 to September 2023, we analyzed data from 12 Nano Aerosol Chemotherapy (NAC) procedures, utilizing oxaliplatin or doxorubicin-cisplatin, in four patients with peritoneal carcinomatosis (PC) of various etiologies. Our investigation focused on tracking the progression of the peritoneal cancer index (PCI).
Results The patients‘ median age was 65 (59; 71) years, and 3 were women. Median PIPAC procedures per patient were 2 (1–3), and all patients underwent more than one NAC procedure. Median PCI at the first NAC was 19 (15–22). PCI decreased for 75% and remained stable for 25%. Overall survival after the first NAC session was 8.6 months (6–10).
Conclusion In conclusion, Nano Aerosol Chemotherapy (NAC) exhibits the potential to impede oncological progression and enhance survival rates. The promising outcomes observed in this study may pave the way for future assessments of NAC through prospective randomized trials.
Disclosures The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
